Cencora
Official SEC filings
Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 01:43 UTC.
| Form | Filed | Original document |
|---|---|---|
| 8-K | 2026-11-04 | Read on SEC.gov |
| 8-K | 2026-11-04 | Read on SEC.gov |
| 8-K | 2026-10-21 | Read on SEC.gov |
| 8-K | 2026-09-25 | Read on SEC.gov |
| 8-K | 2026-08-14 | Read on SEC.gov |
| 8-K | 2026-08-12 | Read on SEC.gov |
| 10-Q | 2026-08-05 | Read on SEC.gov |
| 8-K | 2026-08-05 | Read on SEC.gov |
SEC annual financial snapshot
Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-22 05:51 UTC.
| Metric | USD | Basis | Period end | Filed | Source |
|---|---|---|---|---|---|
| Revenue | $321.33B | Annual | 2025-09-30 | 2025-11-25 | 10-K |
| Net income | $1.55B | Annual | 2025-09-30 | 2025-11-25 | 10-K |
| Operating cash flow | $3.88B | Annual | 2025-09-30 | 2025-11-25 | 10-K |
| Total assets | $76.59B | As of | 2025-09-30 | 2025-11-25 | 10-K |
| Stockholders’ equity | $1.51B | As of | 2025-09-30 | 2025-11-25 | 10-K |
| Cash and cash equivalents | $4.36B | As of | 2025-09-30 | 2025-11-25 | 10-K |
✦ Quant Revenue Concentration how this is computed
- U.S. Healthcare Solutions is the largest reported line at 88.33% of revenue, across 4 reported segments.
- The next-largest line, International Healthcare Solutions, is a distant second at 9.06% - a sharp slowdown here would have little to offset it.
Revenue annual, last 8 years
Latest year +5.00% YoY
Margins
- Gross margin
- 4.11%
- Operating margin
- 1.41%
- Net margin
- 1.03%
Key ratios & quality
- Enterprise valuei
- 71.09B
- PEG ratioi
- 0.73
PEG uses trailing P/E against the 3-year net income growth rate (25.91%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG."
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 179.59B | 189.89B | 213.99B | 238.59B | 262.17B | 293.96B | 321.33B | 337.40B |
| Gross profit | 5.14B | 5.19B | 6.94B | 8.30B | 8.96B | 9.91B | 11.48B | 13.87B |
| Selling & admin expenses | 2.66B | 2.77B | 3.59B | 4.85B | 5.31B | 5.66B | 6.49B | 8.08B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 2.01B | 2.03B | 2.84B | 2.75B | 2.69B | 3.16B | 3.93B | 4.74B |
| Pretax profit | 967.11M | -5.29B | 2.22B | 2.18B | 2.16B | 2.00B | 2.26B | 4.58B |
| Tax | 112.97M | -1.89B | 677.25M | 516.52M | 428.26M | 484.70M | 690.52M | 1.08B |
| Net profit | 854.14M | -3.40B | 1.54B | 1.67B | 1.73B | 1.52B | 1.57B | 3.50B |
| Basic EPS | 4 | -17 | 7 | 8 | 9 | 8 | 8 | 18 |
| Diluted EPS | 4.04 | -16.65 | 7.39 | 8.04 | 8.53 | 7.53 | 7.96 | 17.95 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 80.66B | 83.73B | 85.93B | 78.36B | 84.75B | 88.35B |
| Gross profit | 2.91B | 2.95B | 3.07B | 3.59B | 3.61B | 3.60B |
| Selling & admin expenses | 1.67B | 1.75B | 1.80B | 1.98B | 2.13B | 2.17B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 980.24M | 945.94M | 1.02B | 1.36B | 1.21B | 1.16B |
| Pretax profit | 896.28M | -187.04M | 708.64M | 2.09B | 996.39M | 787.21M |
| Tax | 206.53M | 146.03M | 142.51M | 459.04M | 219.73M | 258.11M |
| Net profit | 689.75M | -333.07M | 566.13M | 1.63B | 776.67M | 529.10M |
| Basic EPS | 4 | -2 | 3 | 8 | 4 | 3 |
| Diluted EPS | 3.52 | -1.75 | 2.87 | 8.40 | 3.94 | 2.71 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 28.13B | 33.06B | 38.80B | 39.59B | 42.80B | 47.72B | 52.24B | 58.45B |
| Cash & ST investments | 3.37B | 4.60B | 2.55B | 3.39B | 2.59B | 3.13B | 4.36B | 4.88B |
| Inventory | 11.06B | 12.59B | 15.37B | 15.56B | 17.45B | 19.00B | 20.49B | 21.36B |
| Total assets | 39.17B | 44.27B | 57.34B | 56.56B | 62.56B | 67.10B | 76.59B | 87.10B |
| Total current liabilities | 29.58B | 33.85B | 41.36B | 43.48B | 48.83B | 54.28B | 57.82B | 62.38B |
| Short-term debt | 139.01M | 501.26M | 300.21M | 1.07B | 641.34M | 576.33M | 117.79M | 203.21M |
| Long-term debt | 4.03B | 3.62B | 6.38B | 4.63B | 4.15B | 3.81B | 7.54B | 11.06B |
| Total liabilities | 36,178,774,000.00 | 45,114,466,000.00 | 56,753,394,000.00 | 56,489,343,000.00 | 61,892,459,000.00 | 66,314,925,000.00 | 74,843,027,000.00 | 83,423,737,000.00 |
| Total equity | 2.99B | -839.64M | 584.41M | 71.27M | 666.29M | 786.74M | 1.75B | 3.68B |
| Retained earnings | 4.24B | 518.34M | 1.67B | 2.98B | 4.32B | 5.42B | 6.53B | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 48.81B | 52.24B | 54.15B | 53.14B | 55.34B | 58.45B |
| Cash & ST investments | 2.23B | 4.36B | 1.75B | 2.18B | 2.82B | 4.88B |
| Inventory | 20.14B | 20.49B | 24.08B | 20.01B | 21.03B | 21.36B |
| Total assets | 73.96B | 76.59B | 78.36B | 81.65B | 83.81B | 87.10B |
| Total current liabilities | 53.96B | 57.82B | 59.13B | 56.13B | 59.20B | 62.38B |
| Short-term debt | 196.79M | 117.79M | 342.28M | 202.66M | 279.16M | 203.21M |
| Long-term debt | 8.04B | 7.54B | 7.58B | 12.18B | 11.44B | 11.06B |
| Total liabilities | 71,747,014,000.00 | 74,843,027,000.00 | 76,265,246,000.00 | 78,067,150,000.00 | 80,566,462,000.00 | 83,423,737,000.00 |
| Total equity | 2.21B | 1.75B | 2.10B | 3.58B | 3.24B | 3.68B |
| Retained earnings | 6.98B | 6.53B | 6.97B | 8.49B | 9.14B | -- |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.34B | 2.21B | 2.67B | 2.70B | 3.91B | 3.48B | 3.88B | 4.79B |
| Depreciation & amortization | 497.51M | 408.01M | 514.79M | 709.84M | 980.85M | 1.12B | 1.07B | -- |
| Free cash flow | 2.03B | 1.84B | 2.23B | 2.21B | 3.45B | 3.00B | 3.21B | 3.88B |
| Dividends paid | -338.97M | -343.58M | -366.65M | -391.69M | -398.75M | -416.17M | -437.08M | -476.81M |
| Stock buybacks / issuance | -674.03M | -354.09M | -82.15M | -483.70M | -1.18B | -1.49B | -435.47M | -1.00B |
| Ending cash balance | 3.37B | 4.60B | 3.07B | 3.59B | 2.75B | 3.30B | 4.39B | 4.97B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 109.25M | 3.13B | -2.31B | 1.34B | 2.65B | 3.10B |
| Depreciation & amortization | 258.97M | 264.00M | 264.27M | 262.98M | 277.43M | -- |
| Free cash flow | -73.97M | 2.88B | -2.42B | 1.17B | 2.43B | 2.70B |
| Dividends paid | -107.49M | -107.51M | -126.52M | -117.46M | -116.59M | -116.25M |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | -1.00B | 0 |
| Ending cash balance | 2.28B | 4.39B | 1.81B | 2.24B | 2.86B | 4.97B |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 29.44 | -366.53 | -- | 28,805.77 | 1,124.39 | 258.42 | 144.31 | 134.27 |
| ROA %i | 2.23 | -8.17 | 3.03 | 2.98 | 2.93 | 2.33 | 2.16 | 4.26 |
| ROIC %i | 13.92 | -65.41 | -- | 30.00 | 35.72 | 31.48 | 24.74 | 32.00 |
| 5-year avg ROE %i | 41.29 | -29.87 | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 0.65 | -2.70 | 1.12 | 1.01 | 0.93 | 0.77 | 0.83 | 1.50 |
| FCF / sales %i | 1.13 | 0.97 | 1.04 | 0.92 | 1.32 | 1.02 | 1.00 | 1.15 |
| Current ratioi | 0.95 | 0.98 | 0.94 | 0.91 | 0.88 | 0.88 | 0.90 | 0.94 |
| Quick ratioi | 0.53 | 0.56 | 0.51 | 0.51 | 0.48 | 0.50 | 0.51 | 0.50 |
| Debt / assetsi | 10.65 | 9.30 | 11.66 | 10.08 | 7.65 | 6.54 | 10.00 | 12.93 |
| LT debt / equityi | 140.12 | -- | 2,858.11 | -- | 794.27 | 590.11 | 500.19 | 300.52 |
| Interest coveragei | 5.95 | -32.39 | 13.17 | 10.41 | 8.84 | 9.06 | 6.38 | 10.35 |
| Revenue CAGR (3Y) %i | 6.94 | 7.43 | 8.41 | 9.93 | 11.35 | 11.16 | 10.43 | 8.77 |
| Net income CAGR (3Y) %i | -15.70 | -- | -2.44 | 25.70 | -- | -0.67 | -2.92 | 25.91 |
| FCF CAGR (3Y) %i | -9.17 | 20.98 | 27.51 | 2.76 | 23.41 | 10.39 | 13.27 | 3.97 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 130.60 | 144.31 | 152.25 | 115.58 | 104.34 | 134.27 |
| ROA %i | 2.70 | 2.16 | 2.20 | 3.34 | 3.33 | 4.26 |
| ROIC %i | 26.09 | 24.74 | 20.43 | 22.88 | 23.53 | 32.00 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 0.93 | 0.83 | 0.86 | 1.21 | 1.24 | 1.50 |
| FCF / sales %i | 0.36 | 1.00 | 1.11 | 0.47 | 1.22 | 1.15 |
| Current ratioi | 0.90 | 0.90 | 0.92 | 0.95 | 0.93 | 0.94 |
| Quick ratioi | 0.50 | 0.51 | 0.47 | 0.48 | 0.48 | 0.50 |
| Debt / assetsi | 11.14 | 10.00 | 10.11 | 15.17 | 13.99 | 12.93 |
| LT debt / equityi | 406.21 | 500.19 | 397.18 | 358.57 | 375.10 | 300.52 |
| Interest coveragei | 8.05 | 6.38 | 6.19 | 8.40 | 8.05 | 10.35 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Quote time 2026-11-20 19:52:19 · For reference only, not investment advice and not tailored to your situation.
Cencora discussion 0 comments